相似文献
1
Cardiovascular injury and repair in chronic obstructive pulmonary disease.
Proc Am Thorac Soc. 2008 Dec 1;5(8):824-33. doi: 10.1513/pats.200807-071TH.
2
Cardiovascular disease in COPD: mechanisms.
Chest. 2013 Mar;143(3):798-807. doi: 10.1378/chest.12-0938.
3
β-Blocker Therapy and Clinical Outcomes in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk. An Observational Substudy of SUMMIT.
Ann Am Thorac Soc. 2018 May;15(5):608-614. doi: 10.1513/AnnalsATS.201708-626OC.
4
Early cardiovascular involvement in chronic obstructive pulmonary disease.
Monaldi Arch Chest Dis. 2009 Jun;71(2):59-65. doi: 10.4081/monaldi.2009.362.
5
[Chronic obstructive pulmonary disease and cardiovascular disease: role of the systemic inflammation].
Recenti Prog Med. 2011 Mar;102(3):109-13. doi: 10.1701/608.7066.
6
Chronic obstructive pulmonary disease: a modifiable risk factor for cardiovascular disease?
Heart. 2012 Jul;98(14):1055-62. doi: 10.1136/heartjnl-2012-301759.
7
Murine models of cardiovascular comorbidity in chronic obstructive pulmonary disease.
Am J Physiol Lung Cell Mol Physiol. 2016 Jun 1;310(11):L1011-27. doi: 10.1152/ajplung.00013.2016. Epub 2016 Mar 18.
8
COPD and stroke: are systemic inflammation and oxidative stress the missing links?
Clin Sci (Lond). 2016 Jul 1;130(13):1039-50. doi: 10.1042/CS20160043.
9
Seasonal and Regional Variations in Chronic Obstructive Pulmonary Disease Exacerbation Rates in Adults without Cardiovascular Risk Factors.
Ann Am Thorac Soc. 2018 Nov;15(11):1296-1303. doi: 10.1513/AnnalsATS.201801-070OC.
10
Chronic obstructive pulmonary disease and obstructive sleep apnea: overlaps in pathophysiology, systemic inflammation, and cardiovascular disease.
Am J Respir Crit Care Med. 2009 Oct 15;180(8):692-700. doi: 10.1164/rccm.200903-0347PP. Epub 2009 Jul 23.
引用本文的文献
1
Echocardiographic Evidence of Left Ventricular Dysfunction in COPD: Relationship with Disease Severity.
Medicina (Kaunas). 2025 Jul 11;61(7):1260. doi: 10.3390/medicina61071260.
2
Systemic Manifestations of COPD and the Impact of Dual Bronchodilation with Tiotropium/Olodaterol on Cardiac Function and Autonomic Integrity.
J Clin Med. 2024 May 16;13(10):2937. doi: 10.3390/jcm13102937.
3
Risk of Ischemic Heart Disease in Chronic Obstructive Pulmonary Disease: A Nationwide Cohort Study.
J Korean Med Sci. 2023 Oct 30;38(42):e344. doi: 10.3346/jkms.2023.38.e344.
4
Associations between spirometric impairments and microvascular complications in type 2 diabetes: a cross-sectional study.
BMJ Open. 2023 Oct 30;13(10):e075209. doi: 10.1136/bmjopen-2023-075209.
5
Systems Engineering Approach to Modeling and Analysis of Chronic Obstructive Pulmonary Disease.
ACS Omega. 2023 May 26;8(23):20524-20535. doi: 10.1021/acsomega.3c00854. eCollection 2023 Jun 13.
6
Treatment effect modification due to comorbidity: Individual participant data meta-analyses of 120 randomised controlled trials.
PLoS Med. 2023 Jun 6;20(6):e1004176. doi: 10.1371/journal.pmed.1004176. eCollection 2023 Jun.
7
The Pleiotropic Role of Vitamin K in Multimorbidity of Chronic Obstructive Pulmonary Disease.
J Clin Med. 2023 Feb 5;12(4):1261. doi: 10.3390/jcm12041261.
8
Standardized airway wall thickness Pi10 from routine CT scans of COPD patients as imaging biomarker for disease severity, lung function decline, and mortality.
Ther Adv Respir Dis. 2023 Jan-Dec;17:17534666221148663. doi: 10.1177/17534666221148663.
9
Risk for Cardiovascular Disease and One-Year Mortality in Patients With Chronic Obstructive Pulmonary Disease and Obstructive Sleep Apnea Syndrome Overlap Syndrome.
Front Pharmacol. 2021 Oct 26;12:767982. doi: 10.3389/fphar.2021.767982. eCollection 2021.
10
Cardiovascular risk prediction using physical performance measures in COPD: results from a multicentre observational study.
BMJ Open. 2020 Dec 28;10(12):e038360. doi: 10.1136/bmjopen-2020-038360.
本文引用的文献
1
Impact of cardioselective beta-blockers on mortality in patients with chronic obstructive pulmonary disease and atherosclerosis.
Am J Respir Crit Care Med. 2008 Oct 1;178(7):695-700. doi: 10.1164/rccm.200803-384OC. Epub 2008 Jun 19.
2
Expanding the concept of telomere dysfunction in cardiovascular disease.
Arterioscler Thromb Vasc Biol. 2008 May;28(5):807-8. doi: 10.1161/ATVBAHA.108.164434.
3
The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease.
Am J Respir Crit Care Med. 2008 Jun 1;177(11):1207-14. doi: 10.1164/rccm.200709-1356OC. Epub 2008 Feb 28.
4
Inflammatory mechanisms: the molecular basis of inflammation and disease.
Nutr Rev. 2007 Dec;65(12 Pt 2):S140-6. doi: 10.1111/j.1753-4887.2007.tb00352.x.
5
Impact of chronic obstructive pulmonary disease on long-term outcome of patients hospitalized for heart failure.
Am J Cardiol. 2008 Feb 1;101(3):353-8. doi: 10.1016/j.amjcard.2007.08.046. Epub 2007 Dec 21.
6
Cellular senescence, cardiovascular risk, and CKD: a review of established and hypothetical interconnections.
Am J Kidney Dis. 2008 Jan;51(1):131-44. doi: 10.1053/j.ajkd.2007.07.035.
7
Atherosclerosis and oxidative stress.
Histol Histopathol. 2008 Mar;23(3):381-90. doi: 10.14670/HH-23.381.
8
Recent respiratory infection and risk of cardiovascular disease: case-control study through a general practice database.
Eur Heart J. 2008 Jan;29(1):96-103. doi: 10.1093/eurheartj/ehm516. Epub 2007 Dec 6.
9
Increased arterial stiffness in patients with chronic obstructive pulmonary disease: a mechanism for increased cardiovascular risk.
Thorax. 2008 Apr;63(4):306-11. doi: 10.1136/thx.2007.083493. Epub 2007 Nov 16.
10
Use of beta blockers and the risk of death in hospitalised patients with acute exacerbations of COPD.
Thorax. 2008 Apr;63(4):301-5. doi: 10.1136/thx.2007.081893. Epub 2007 Oct 19.
Zotero 插件